Actively Recruiting
Daily Doxycycline for Early Syphillis
Led by University of Washington · Updated on 2025-06-25
15
Participants Needed
1
Research Sites
68 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if doxycycline taken as 200mg daily for 14 days is effective to treat early stage syphilis. This is different from how doxycycline is typically used for syphilis because the full doxycycline dose will be taken at the same time of day, rather than split up into a twice daily regimen. Lab data support that taking the medication as a single daily dose should be effective as treatment, but it has not been studied clinically. The main question this study aims to answer is: Is doxycycline taken as a single daily dose of 200mg for 14 days an effective treatment for early syphilis based on a combined outcome of clinical improvement and blood test improvement? Participants will: 1. Take doxycycline 200mg daily for 14 days 2. Submit oral and rectal swabs that test for syphilis bacteria every other day for 2 weeks, returned by mail 3. Complete 2 brief online surveys over the first 2 weeks 4. Return to the clinic for an interview and blood draw every 3 months for a maximum of 3 study visits, including the first visit The investigators will compare the percentage of participants in the study who have response to treatment by 6 months to that of persons who have received standard (CDC-recommended) regimens. To do this, the investigators will calculate response percentage estimates following a shot of long-acting penicillin or 14 days of doxycycline 100mg twice daily from 60-person samples from the sexual health program's records.
CONDITIONS
Official Title
Daily Doxycycline for Early Syphillis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of primary or secondary syphilis or laboratory-confirmed early latent syphilis within the past 31 days
- Clinical diagnosis of primary syphilis with a positive qualitative RPR or positive darkfield microscope exam from a chancre
- Clinical diagnosis of secondary syphilis with a positive qualitative RPR
- Laboratory-confirmed early latent syphilis within one month prior to enrollment
- Age 18 years or older
You will not qualify if you...
- Age under 18 years
- Evidence of neurosyphilis (including ocular and otic syphilis) or tertiary syphilis
- Unable to give informed consent
- Unable to complete study follow-up visits
- Allergy to doxycycline
- Pregnant persons
- Persons with HIV who are off antiretroviral medication or not virologically suppressed
- Other known immunosuppression (e.g., systemic immunosuppressant drugs, primary immunodeficiencies)
- Taking medications that interact with doxycycline
- Initial RPR lower than 1:4
- Currently prescribed doxycycline post-exposure prophylaxis (PEP)
- Breastfeeding persons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Public Health Sexual Health Clinic
Seattle, Washington, United States, 98104
Actively Recruiting
Research Team
T
Travis Hunt, MD
CONTACT
M
Matthew Golden, MD, MPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here